Table 1 General characteristics of study participants at baseline study
From: Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients
|  | Placebo group (n = 30) | Vitamin D plus probiotic group (n = 30) | P1 |
|---|---|---|---|
Age (y) | 43.2 ± 6.0 | 44.8 ± 8.3 | 0.41 |
Gender | |||
 Female | 2 (6.7) | 2 (6.7) | > 0.99†|
 Male | 28 (93.3) | 28 (93.3) |  |
Height (m) | 168.6 ± 7.5 | 170.6 ± 6.0 | 0.24 |
Weight at study baseline (kg) | 69.5 ± 10.7 | 67.2 ± 9.0 | 0.38 |
Weight at end-of-trial (kg) | 69.5 ± 10.5 | 67.5 ± 8.7 | 0.42 |
Body weight change (kg) | 0.04 ± 0.7 | 0.2 ± 1.2 | 0.43 |
BMI at study baseline (kg/m2) | 24.5 ± 3.7 | 23.1 ± 2.8 | 0.11 |
BMI at end-of-trial (kg/m2) | 24.5 ± 3.7 | 23.2 ± 2.7 | 0.12 |
BMI change (kg/m2) | 0.01 ± 0.2 | 0.1 ± 0.4 | 0.46 |